Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease
Overview
Neurology
Authors
Affiliations
Background: Peripheral (plasma) and central (cerebrospinal fluid, CSF) measures of tau are higher in Alzheimer's disease (AD) relative to prodromal stages and controls. While elevated CSF tau concentrations have been shown to be associated with lower grey matter density (GMD) in AD-specific regions, this correlation has yet to be examined for plasma in a large study.
Objective: Determine the neuroanatomical correlates of plasma tau using voxel-based analysis.
Methods: Cross-sectional data for 508 ADNI participants were collected for clinical, plasma total-tau (t-tau), CSF amyloid (Aβ42) and tau, and MRI variables. The relationship between plasma tau and GMD and between CSF t-tau and GMD were assessed on a voxel-by-voxel basis using regression models. Age, sex, APOEɛ4 status, diagnosis, and total intracranial volume were used as covariates where appropriate. Participants were defined as amyloid positive (Aβ+) if CSF Aβ42 was <192 pg/mL.
Results: Plasma tau was negatively correlated with GMD in the medial temporal lobe (MTL), precuneus, thalamus, and striatum. The associations with thalamus and striatum were independent of diagnosis. A negative correlation also existed between plasma tau and GMD in Aβ+ participants in the MTL, precuneus, and frontal lobe. When compared to CSF t-tau, plasma tau showed a notably different associated brain atrophy pattern, with only small overlapping regions in the fusiform gyrus.
Conclusion: Plasma tau may serve as a non-specific marker for neurodegeneration but is still relevant to AD considering low GMD was associated with plasma tau in Aβ+ participants and not Aβ-participants.
Plasma biomarkers of amyloid, tau, astrogliosis, and axonal injury in a mixed memory clinic cohort.
Gleerup H, Simonsen A, Grotschel L, Gramkow M, Hogh P, Blennow K Alzheimers Dement (Amst). 2025; 17(1):e70073.
PMID: 39822295 PMC: 11736635. DOI: 10.1002/dad2.70073.
Associations of plasma biomarkers with cerebral perfusion and structure in Alzheimer's disease.
He Y, Liu X, Liu F, Che P, Zhang Y, Fan R Transl Psychiatry. 2025; 15(1):2.
PMID: 39762217 PMC: 11704010. DOI: 10.1038/s41398-024-03220-3.
Duggan M, Yang Z, Cui Y, Dark H, Wen J, Erus G Alzheimers Dement. 2024; 20(9):6486-6505.
PMID: 39129354 PMC: 11497673. DOI: 10.1002/alz.14142.
Management of MCI in the Outpatient Setting.
Abramowitz A, Weber M Curr Psychiatry Rep. 2024; 26(8):413-421.
PMID: 38856858 DOI: 10.1007/s11920-024-01514-3.
Piel J, Bargemann L, Leypoldt F, Wandinger K, Dargvainiene J Front Neurol. 2024; 15:1356575.
PMID: 38566855 PMC: 10985356. DOI: 10.3389/fneur.2024.1356575.